权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PROJECT 2

项目2

基本信息

批准号：
10225390
负责人：
Daniel A Harki
金额：
$ 36.09万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-09 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10225390
关键词：
Achievement Address Advanced Development Animal Model Animals Antibody Formation Antiviral Agents Automobile Driving BRCA1 gene Binding Biochemical Biochemistry Biological Biological Assay Biology Biophysics Breast Breast Cancer Cell Breast Cancer Model Cells Cellular Assay Chemicals Clinical Collaborations Complex Crystallization Cytosine DNA DNA Binding DNA Sequence Deaminase Deamination Defect Deoxycytidine Development Drug resistance Enzyme Inhibition Enzymes Estrogen receptor positive Evolution Foundations Future Goals Graph Inherited Lead Ligand Binding Ligands Malignant Neoplasms Mammary Neoplasms Mediating Metastatic breast cancer Methods Modeling Modification Molecular Mutagenesis Mutate Mutation Neoplasm Metastasis Nucleic Acid Probes Nucleic Acids Nucleotides Oligonucleotides Outcome PIK3CA gene Physiological Positioning Attribute Primary Neoplasm Process Proteins RNA Reagent Reporting Research Resistance Roentgen Rays Role Services Single-Stranded DNA Structure Technology Testing The Cancer Genome Atlas Therapeutic Treatment Failure Uracil Variant Virus Diseases Work base clinical translation computational chemistry design drug development drug discovery experimental study feature detection forging homologous recombination improved in vivo inhibitor/antagonist innovation malignant breast neoplasm molecular recognition mouse model multidisciplinary novel novel strategies overexpression preference prevent programs small molecule small molecule inhibitor structural biology therapeutic development therapy outcome tumor

项目摘要

PROJECT 2 – CHEMICAL BIOLOGY OF DNA DEAMINASES IN BREAST CANCER ABSTRACT APOBEC enzymes are single-stranded DNA cytosine-to-uracil deaminases that normally protect cells from viral infections. However, APOBEC3B (A3B) has been implicated in mutations in breast cancer that drive tumor evolution and contribute to the development of drug resistance and, ultimately, therapy failure. A3B is overexpressed in over half of all estrogen receptor (ER)-positive breast tumors, the most common type, and is associated with poor overall survival. Our Program has shown that inhibition of A3B-mediated tumor evolution improves therapy outcomes in a mouse model of ER-positive breast cancer. Our Program’s unifying hypothesis is that A3B inhibition will prevent a large proportion of new mutations in ER-positive breast cancer, thereby improving the durability of current treatments and resulting in better overall outcomes. To address this hypothesis our Program is focused on understanding the biology of A3B in breast cancer cells (Project 1); developing innovative nucleic acid probes to molecularly characterize how A3B engages DNA substrates and small molecules to inhibit A3B-catalyzed breast cancer mutations (Project 2); and generating A3B x-ray structures with nucleic acids, small molecules, and protein ligands to understand the structural basis of A3B- mediated DNA mutagenesis and its inhibition to enable development of therapeutic compounds (Project 3). These activities will be supported by Service Cores for administration (Core A), animal models of A3B-driven breast cancer (Core B), computational chemistry and biophysics (Core C), and protein and antibody production (Core D). Project 2 – Chemical Biology of DNA Deaminases in Breast Cancer will lead the chemical probe discovery efforts by 1) synthesizing complex nucleic acid ligands for A3B to characterize how A3B discriminates 2¢-deoxycytidine from other nucleotides and to understand which nucleic acid features enable A3B to deaminate discrete DNA sequences, including its overall preference for binding DNA versus RNA; and 2) using complimentary technologies and approaches to develop first-in-class small molecule inhibitors of A3B that will be used in mechanistic cellular assays of A3B-driven breast cancer mutation (Project 1), structural biology studies to annotate A3B-ligand binding (Project 3), and therapeutic utility experiments in animal models of breast cancer (Core B). Our studies will be enabled by critical collaborations involving computational ligand design (Core C) and access to high-quality biological reagents for assays (Core D), and our advances will position our novel compounds for future therapeutic development. Potent, selective chemical probes of A3B with in vivo activity, as well as novel assays, are the major anticipated deliverables of Project 2. As such, Project 2 will be the center of chemical innovation for the Program, accelerating all Projects and contributing to the achievement of our overall research objectives.

项目二：乳腺癌DNA脱氨酶的化学生物学研究